# Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults

> **NCT00980447** · PHASE2 · COMPLETED · sponsor: **UMN Pharma Inc.** · enrollment: 90 (actual)

## Conditions studied

- Influenza
- Virus Diseases

## Interventions

- **BIOLOGICAL:** UMN-0501
- **BIOLOGICAL:** UMN-0501
- **BIOLOGICAL:** UMN-0501

## Key facts

- **NCT ID:** NCT00980447
- **Lead sponsor:** UMN Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2010-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00980447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00980447, "Immunogenicity, Safety and Optimal Dose Finding Study of Recombinant Influenza H5N1 Vaccine in Healthy Young Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00980447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*